ATS Active, 600 mg sachet 1,6mg 10 pcs

Interaction

The concomitant use of acetylcysteine with anti-cough drugs may result in bronchial sputum congestion due to suppression of the cough reflex. A careful evaluation of the patient is necessary before such combination therapy is prescribed.

The current reports of inactivation by acetylcysteine of antibacterial drugs such as tetracyclines (except doxycycline), aminoglycosides, cephalosporins, penicillins (ampicillin), and antifungal drugs (amphotericin B) refer exclusively to in vitro studies (pharmaceutical incompatibility). Nevertheless, oral antibacterials and Atsz® Active should be used at least 2 hours apart (not applicable to cefixime and loracarbef).

The concomitant use with acetylcysteine may increase the vasodilatory and antiplatelet effects of nitroglycerin. If concomitant use of nitroglycerin and acetylcysteine is required, the patient should be monitored for the potential development of arterial hypotension (sometimes severe, may manifest as headache).

The concomitant use of acetylcysteine and carbamazepine may result in reduction of carbamazepine concentrations to subtherapeutic levels.

The concomitant use of activated charcoal may decrease the effect of acetylcysteine.

Acetylcysteine eliminates the toxic effects of paracetamol.

Directions for use

Internal. The powder from 1 sachet should be poured directly on the tongue. The drug stimulates salivation, so the powder is mixed with saliva and easily swallowed. It is not recommended to wash down with water. Oral powder should not be chewed before swallowing.

Adults: 1 sachet once daily (equivalent to 600 mg of acetylcysteine per day).

Because of the high content of acetylcysteine (600 mg) in 1 sachet, the drug should not be used in children (other dosage forms of AtsC® or other acetylcysteine preparations are recommended).

The duration of treatment should be evaluated individually. In case of short-term colds the course duration is 5-7 days, in case of treatment of chronic diseases – up to several months (according to the doctor’s recommendation).

Special Instructions

In patients with bronchial asthma and obstructive bronchitis, acetylcysteine should be administered with caution under systemic control of bronchial patency. If the patient is unable to expectorate effectively, drainage or aspiration of the secretion should be performed.

In the use of acetylcysteine, severe allergic reactions such as Stevens-Johnson syndrome and Lyell syndrome have very rarely been reported. If changes of the skin and mucous membranes occur, it is necessary to consult a physician immediately, the drug should be discontinued.

Do not take the drug immediately before going to bed (it is recommended to take the drug before 6 pm).

The effect on laboratory data. Acetylcysteine may affect the results of colorimetric determination of plasma concentration of salicylates. In urinalysis, acetylcysteine may affect the results of ketone body determination.

Influence on the ability to drive vehicles, mechanisms

Acetylcysteine has no effect on the ability to drive vehicles and operate mechanisms.

.

Synopsis

Powder from white to yellowish-white color with easily disintegrated agglomerates, with a smell of blackberries. A faint sulfuric odor may be present.

Features

Acetylcysteine is quickly and almost completely absorbed when taken orally. Due to high presystemic metabolism (effect of “primary passage” through the liver) the bioavailability of oral forms of acetylcysteine is about 10%. Maximal concentration (Cmax) of acetylcysteine in blood plasma after oral administration is reached after 1-3 hours and is 15 mmol/l, Cmax of cysteine metabolite is approximately 2 µmol/l.

Distribution

The binding to plasma proteins is about 50% after 4 h and decreases to 20% after 12 h.

Acetylcysteine is distributed both unchanged (20%) and in the form of active metabolites (80%), penetrates into intercellular space, distributed mainly in liver, kidneys, lungs and bronchial secretion. Acetylcysteine penetrates the placental barrier and is determined in umbilical cord blood. There is no information on excretion into breast milk. There are no data on the ability of acetylcysteine to penetrate the blood-brain barrier.

Metabolism

Acetylcysteine is metabolized in the liver to cysteine, a pharmacologically active metabolite, as well as to diacetylcysteine, cystine and other mixed disulfides. In the body acetylcysteine and its metabolites can be detected in different forms: in free form, bound to plasma proteins by labile disulfide bonds or as bound amino acids.

Acetylcysteine is excreted almost exclusively as inactive metabolites (inorganic sulfates, diacetylcysteine) by the kidneys, a small portion is excreted unchanged through the intestine. The blood plasma elimination half-life (T1/2) is approximately 1 hour and depends on the rate of biotransformation in the liver. In patients with liver dysfunction T1/2 of acetylcysteine may be increased up to 8 hours.

Contraindications

• High sensitivity to acetylcysteine or other drug components
• bleeding, pulmonary hemorrhage
• Gastric and duodenal ulcer in the acute stage
• peptic ulcer
• children under 18 years of age (for this dosage form);
• pregnancy and breastfeeding
• hereditary intolerance to fructose (contains sorbitol), phenylketonuria (contains the source of aspartame phenylalanine).

With caution

History of gastric or duodenal ulcer, bronchial asthma, obstructive bronchitis, hepatic and/or renal insufficiency, histamine intolerance (long-term use should be avoided,

because acetylcysteine affects histamine metabolism, which may lead to the appearance of symptoms of intolerance, such as headache, vasomotor rhinitis, itching), esophageal varices, adrenal disorders, arterial hypertension.

Side effects

According to the World Health Organization (WHO) adverse reactions are classified according to their frequency of development as follows: very common (≥1/10), common (≥1/100 to < 1/10), infrequent (≥1/1000 to < 1/100), rare (≥1/10000 to < 1/1000), very rare (< 1/10000); frequency is unknown – according to available data it was impossible to determine the frequency of occurrence.
Immune system disorders

infrequent: hypersensitivity reactions;

very rare: anaphylactic shock, anaphylactic/anaphylactoid reactions.

Nervous system disorders

infrequent: headache.

Heart and vascular disorders

infrequent: tachycardia, arterial hypotension;

very rare: bleeding*;

frequency unknown: cases of collapse have been described when acetylcysteine is taken.

Respiratory system disorders

rarely: dyspnea, bronchospasm (mainly in patients with bronchial hyperresponsiveness due to bronchial asthma).

Gastrointestinal disorders

infrequent: abdominal pain, nausea, vomiting, diarrhea, stomatitis;

rarely: dyspepsia;

frequency unknown: heartburn.

Skin and subcutaneous tissue disorders

frequent: urticaria, exanthema, rash, angioedema, pruritus;

very rare: Stevens-Johnson syndrome, Lyell’s syndrome (see section “Special Indications”).

Hearing and labyrinth disorders

infrequent: tinnitus.

General disorders

infrequent: fever;

frequency unknown: facial edema.

* Single reports of bleeding with acetylcysteine, sometimes together with hypersensitivity reactions. Decrease of platelet aggregation with acetylcysteine has been confirmed in some studies; clinical significance of this phenomenon has not yet been determined.

Overdose

Toxic overdose in oral acetylcysteine has not been described. Acetylcysteine when administered in doses up to 500 mg/kg/day did not cause symptoms of overdose. Healthy volunteers received acetylcysteine at a dose of 11.6 g per day for 3 months without developing any serious adverse reactions.

Symptoms: gastrointestinal manifestations such as nausea, vomiting, and diarrhea may be observed.

Treatment: symptomatic therapy if necessary.

Similarities

Atsc, Atsc 200, Atsc-long, Acetylcysteine, Fluimucil, Acetylcysteine Canon, Espa-Naz, Eifa AC